Sign in or Register   Sign in or Register
  |  

Mouse Anti-CYP19A1 Recombinant Antibody (H4) (CBMAB-1513-CN)

This product is a mouse antibody that recognizes CYP19A1 of human. The antibody H4 can be used for immunoassay techniques such as: IHC-P, WB.
See all CYP19A1 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
H4
Antibody Isotype
IgG2a
Application
IHC-P, WB

Basic Information

Immunogen
Synthetic peptide corresponding to aa. 376-390 (KALEDDVIDGYPVKK) of Human Aromatase.
Specificity
Human
Antibody Isotype
IgG2a
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Preservative
0.09% Sodium azide
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Cytochrome P450 Family 19 Subfamily A Member 1
Introduction
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and catalyzes the last steps of estrogen biosynthesis. This protein catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Entrez Gene ID
1588
UniProt ID
P11511
Alternative Names
ARO; ARO1; CPV1; CYAR; CYP19; CYPXIX; P-450AROM
Function
A cytochrome P450 monooxygenase that catalyzes the conversion of C19 androgens, androst-4-ene-3,17-dione (androstenedione) and testosterone to the C18 estrogens, estrone and estradiol, respectively (PubMed:27702664, PubMed:2848247).

Catalyzes three successive oxidations of C19 androgens: two conventional oxidations at C19 yielding 19-hydroxy and 19-oxo/19-aldehyde derivatives, followed by a third oxidative aromatization step that involves C1-beta hydrogen abstraction combined with cleavage of the C10-C19 bond to yield a phenolic A ring and formic acid (PubMed:20385561).

Alternatively, the third oxidative reaction yields a 19-norsteroid and formic acid. Converts dihydrotestosterone to delta1,10-dehydro 19-nordihydrotestosterone and may play a role in homeostasis of this potent androgen (PubMed:22773874).

Also displays 2-hydroxylase activity toward estrone (PubMed:22773874).

Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:20385561, PubMed:22773874).
Biological Process
Androgen catabolic process Source: CAFA
Estrogen biosynthetic process Source: Reactome
Female gonad development Source: GO_Central
Positive regulation of estradiol secretion Source: CAFA
Response to estradiol Source: GO_Central
Steroid biosynthetic process Source: ProtInc
Sterol metabolic process Source: Reactome
Cellular Location
Endoplasmic reticulum membrane; Microsome membrane
Involvement in disease
Aromatase excess syndrome (AEXS):
An autosomal dominant disorder characterized by increased extraglandular aromatization of steroids that presents with heterosexual precocity in males and isosexual precocity in females.
Aromatase deficiency (AROD):
A rare disease in which fetal androgens are not converted into estrogens due to placental aromatase deficiency. Thus, pregnant women exhibit a hirsutism, which spontaneously resolves after post-partum. At birth, female babies present with pseudohermaphroditism due to virilization of extern genital organs. In adult females, manifestations include delay of puberty, breast hypoplasia and primary amenorrhoea with multicystic ovaries.
PTM
Phosphorylated in vitro by PKA and PKG/PRKG1. These phosphorylations inhibit the catalytic activity as measured by estrone synthesis from androstenedione (36% decrease for PKA and 30% for PKG/PRKG1).

Parween, S., Fernández-Cancio, M., Benito-Sanz, S., Camats, N., Rojas Velazquez, M. N., López-Siguero, J. P., ... & Pandey, A. V. (2020). Molecular basis of CYP19A1 deficiency in a 46, XX patient with R550W mutation in POR: Expanding the PORD phenotype. The Journal of Clinical Endocrinology & Metabolism, 105(4), e1272-e1290.

Hosseini, E., Shahhoseini, M., Afsharian, P., Karimian, L., Ashrafi, M., Mehraein, F., & Afatoonian, R. (2019). Role of epigenetic modifications in the aberrant CYP19A1 gene expression in polycystic ovary syndrome. Archives of medical science: AMS, 15(4), 887.

Khayeka-Wandabwa, C., Ma, X., Cao, X., Nunna, V., Pathak, J. L., Bernhardt, R., ... & Bureik, M. (2019). Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans. International immunopharmacology, 73, 64-71.

Kaur, R., Kaur, T., & Kaur, A. (2018). Genetic association study from North India to analyze association of CYP19A1 and CYP17A1 with polycystic ovary syndrome. Journal of assisted reproduction and genetics, 35(6), 1123-1129.

Kaewlert, W., Sakonsinsiri, C., Namwat, N., Sawanyawisuth, K., Ungarreevittaya, P., Khuntikeo, N., ... & Thanan, R. (2018). The importance of CYP19A1 in estrogen receptor-positive cholangiocarcinoma. Hormones and Cancer, 9(6), 408-419.

Castro-Piedras, I., Sharma, M., den Bakker, M., Molehin, D., Martinez, E. G., Vartak, D., ... & Pruitt, K. (2018). DVL1 and DVL3 differentially localize to CYP19A1 promoters and regulate aromatase mRNA in breast cancer cells. Oncotarget, 9(86), 35639.

El-Bayomi, K. M., Saleh, A. A., Awad, A., El-Tarabany, M. S., El-Qaliouby, H. S., Afifi, M., ... & El-Magd, M. A. (2018). Association of CYP19A1 gene polymorphisms with anoestrus in water buffaloes. Reproduction, Fertility and Development, 30(3), 487-497.

Magnani, L., Frige, G., Gadaleta, R. M., Corleone, G., Fabris, S., Kempe, H., ... & Minucci, S. (2017). Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. Nature genetics, 49(3), 444-450.

Flück, C. E., & Pandey, A. V. (2017). Impact on CYP19A1 activity by mutations in NADPH cytochrome P450 oxidoreductase. The Journal of steroid biochemistry and molecular biology, 165, 64-70.

Wang, J., & Gong, Y. (2017). Transcription of CYP19A1 is directly regulated by SF-1 in the theca cells of ovary follicles in chicken. General and Comparative Endocrinology, 247, 1-7.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CYP19A1 Recombinant Antibody (H4)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare